211 research outputs found

    New data on OZI rule violation in bar{p}p annihilation at rest

    Full text link
    The results of a measurement of the ratio R = Y(phi pi+ pi-) / Y(omega pi+ pi-) for antiproton annihilation at rest in a gaseous and in a liquid hydrogen target are presented. It was found that the value of this ratio increases with the decreasing of the dipion mass, which demonstrates the difference in the phi and omega production mechanisms. An indication on the momentum transfer dependence of the apparent OZI rule violation for phi production from the 3S1 initial state was found.Comment: 11 pages, 3 PostScript figures, submitted to Physics Letter

    Results of the coupled channel analysis of π+π−π0, K+K−π0 and K±K0Sπ∓ final states from p̄p annihilation at rest in hydrogen targets at different densities

    Get PDF
    n/

    Study of the f(0)(1500)/f(2)(1565) production in the exclusive annihilation anti-n.anti-p -> pi+.pi+.pi- in flight

    Get PDF
    The spin-parity analysis of the (n) over bar p --> pi(+)pi(+)pi(-) exclusive reaction in flight is presented. The main aim is to study the (pi(+)pi(-)) invariant mass spectrum in the region around 1500 MeV. The analysis was performed with a Breit-Wigner parametrization for all the resonant states and, for the scalar sector in the mass region below 1.2 GeV, by means of a K-matrix-like treatment. It clearly shows the need for two states, a scalar one (0(++)) with mass and width (1522+/-25) MeV and (108+/-33) MeV, and a tensorial one (2(++)) with mass (1575 +/-18) MeV and width (119+/-24) MeV, respectively. In addition, the analysis requires the presence of a scalar state at (1280+/-55) MeV, (323+/-13) MeV broad, and of a second vectorial one, in addition to the rho(0)(770) signal, with mass and width (1348+/-33) MeV and (275+/-10) MeV, respectively

    Immune effector cell-associated hematotoxicity (ICAHT): EHA/EBMT consensus grading and best practice recommendations

    Get PDF
    Hematological toxicity represents the most common adverse event following chimeric antigen receptor (CAR) T-cell therapy. Cytopenias can be profound, long-lasting, and can predispose for severe infectious complications. In a recent worldwide survey, we demonstrated that there remains considerable heterogeneity in regards to current practice patterns. Here, we sought to build consensus on the grading and management of Immune Effector Cell Associated Hemato-Toxicity (ICAHT) following CAR-T therapy. For this purpose, a joint effort between the European society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA) involved an international panel of 36 CAR-T experts who met in a series of virtual conferences, culminating in a 2-day meeting in Lille, France. On the basis of these deliberations, best practice recommendations were developed. For the grading of ICAHT, a classification system based on depth and duration of neutropenia was developed for early (day 0-30) and late cytopenia (after day +30). Detailed recommendations on risk factors, available pre-infusion scoring systems (e.g. CAR-HEMATOTOX score), and diagnostic work-up are provided. A further section focuses on identifying hemophagocytosis in the context of severe hematotoxicity. Finally, we review current evidence and provide consensus recommendations for the management of ICAHT, including growth factor support, anti-infectious prophylaxis, transfusions, autologous hematopoietic cell boost, and allogeneic hematopoietic cell transplantation. In conclusion, we propose ICAHT as a novel toxicity category following immune effector cell therapy, provide a framework for its grading, review literature on risk factors, and outline expert recommendations for the diagnostic work-up and short- and long-term management
    • …
    corecore